Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.7
3.0
Journals
Diagnostics
Special Issues
Advances in the Diagnosis of Eye Diseases
share announcement

Advances in the Diagnosis of Eye Diseases

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".

Deadline for manuscript submissions: 31 March 2025 | Viewed by 2119

Special Issue Editor

Dr. Ivan Tanev

E-Mail Website
Guest Editor
Eye Clinic Zrenieto, 1000 Sofia, Bulgaria
Interests: ophthalmology; glaucoma; age-related macular degeneration

Special Issue Information

Dear Colleagues,

Eye diseases, such as cataracts, glaucoma, age-related macular degeneration, and diabetic retinopathy, continue to represent leading causes of vision impairment and blindness worldwide. Timely and accurate diagnosis is crucial in providing appropriate treatment and preventing irreversible vision loss. Hence, this Special Issue will highlight cutting-edge research, innovative technologies, and novel approaches that are improving the early detection, diagnosis, and monitoring of eye diseases.

We invite researchers to submit original research findings, review articles, and case studies that demonstrate advancements in diagnostic tools, imaging techniques, biomarkers, artificial intelligence applications, and other innovative approaches to the diagnosis of eye diseases.

Overall, the goal of this Special Issue is to provide a platform for sharing and disseminating the latest developments in the diagnosis of eye diseases, ultimately leading to improved patient outcomes and better management of eye health. We hope that this Special Issue will inspire further research and innovation in this critical area of ophthalmology.

Dr. Ivan Tanev
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cataracts
  • glaucoma
  • age-related macular degeneration
  • diabetic retinopathy
  • OCT
  • artificial intelligence

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 2214 KiB  
Article
Influence of Aflibercept on Choroidal Blood Flow and Thickness in Branch Retinal Vein Occlusion: A Six-Month Follow-Up Study
by Ryuya Hashimoto, Kenichiro Aso, Keisuke Yata, Kazufumi Tanaka, Naoki Fujioka, Ryo Yamazaki, Serika Moriyama, Juri Kawamura, Asato Hirota and Takatoshi Maeno
Diagnostics 2024, 14(22), 2484; https://doi.org/10.3390/diagnostics14222484 - 7 Nov 2024
Viewed by 388
Abstract
Background/Objectives: We intended to investigate choroidal blood flow (CBF) and choroidal thickness (CT) alternations in treatment-naive eyes with non-ischemic branch retinal vein occlusion (BRVO) following intravitreal aflibercept injection (IVA). Methods: Twenty eyes of 20 patients with treatment-naive non-ischemic BRVO, treated with IVA 1+ [...] Read more.
Background/Objectives: We intended to investigate choroidal blood flow (CBF) and choroidal thickness (CT) alternations in treatment-naive eyes with non-ischemic branch retinal vein occlusion (BRVO) following intravitreal aflibercept injection (IVA). Methods: Twenty eyes of 20 patients with treatment-naive non-ischemic BRVO, treated with IVA 1+ pro re nata, were included in this study. In the BRVO eyes, CBF and CT were measured in the occlusive region, subfovea, as well as the non-occlusive region, via laser speckle flowgraphy (LSFG) and enhanced depth-imaging optical coherence tomography over a 6-month follow-up period. CBF was analyzed via the mean blur rate using LSFG analysis software (version 3.10.0). Results: CT showed significant reductions in both the occlusive and subfoveal region at 1 week and 1 month after treatment (both p < 0.05). CBF was significantly decreased in the subfovea and the non-occlusive region at 1 week and 1 month from baseline, respectively (both p < 0.05). The mean number of IVA injections during the 6-month period was 1.95 ± 0.6. Conclusions: Aflibercept treatment reduced CBF and CT in addition to a decrease in retinal thickness. These changes at each region might be associated with the improvement of macular edema in BRVO eyes. Full article
(This article belongs to the Special Issue Advances in the Diagnosis of Eye Diseases)
►▼ Show Figures

Figure 1

8 pages, 229 KiB  
Article
Evaluating Diagnostic Concordance in Primary Open-Angle Glaucoma Among Academic Glaucoma Subspecialists
by Chenmin Wang, De-Fu Chen, Xiao Shang, Xiaoyan Wang, Xizhong Chu, Chengju Hu, Qiangjie Huang, Gangwei Cheng, Jianjun Li, Ruiyi Ren and Yuanbo Liang
Diagnostics 2024, 14(21), 2460; https://doi.org/10.3390/diagnostics14212460 - 3 Nov 2024
Viewed by 758
Abstract
Objective: The study aimed to evaluate the interobserver agreement among glaucoma subspecialists in diagnosing glaucoma and to explore the causes of diagnostic discrepancies. Methods: Three experienced glaucoma subspecialists independently assessed frequency domain optical coherence tomography, fundus color photographs, and static perimetry results from [...] Read more.
Objective: The study aimed to evaluate the interobserver agreement among glaucoma subspecialists in diagnosing glaucoma and to explore the causes of diagnostic discrepancies. Methods: Three experienced glaucoma subspecialists independently assessed frequency domain optical coherence tomography, fundus color photographs, and static perimetry results from 464 eyes of 275 participants, adhering to unified glaucoma diagnostic criteria. All data were collected from the Wenzhou Glaucoma Progression Study between August 2014 and June 2021. Results: The overall interobserver agreement among the three experts was poor, with a Fleiss’ kappa value of 0.149. The kappa values interobserver agreement between pairs of experts ranged from 0.133 to 0.282. In 50 cases, or approximately 10.8%, the three experts reached completely different diagnoses. Agreement was more likely in cases involving larger average cup-to-disc ratios, greater vertical cup-to-disc ratios, more severe visual field defects, and thicker retinal nerve fiber layer measurements, particularly in the temporal and inferior quadrants. High myopia also negatively impacted interobserver agreement. Conclusions: Despite using unified diagnostic criteria for glaucoma, significant differences in interobserver consistency persist among glaucoma subspecialists. To improve interobserver agreement, it is recommended to provide additional training on standardized diagnostic criteria. Furthermore, for cases with inconsistent diagnoses, long-term follow-up is essential to confirm the diagnosis of glaucoma. Full article
(This article belongs to the Special Issue Advances in the Diagnosis of Eye Diseases)
14 pages, 6871 KiB  
Article
Baseline Choroidal Blood Flow Imbalance as a Predictive Factor for Macular Edema Recurrence Secondary to Branch Retinal Vein Occlusion
by Ryuya Hashimoto, Kenichiro Aso, Keisuke Yata, Naoki Fujioka, Kazufumi Tanaka, Serika Moriyama, Asato Hirota, Juri Kawamura and Takatoshi Maeno
Diagnostics 2024, 14(20), 2328; https://doi.org/10.3390/diagnostics14202328 - 18 Oct 2024
Cited by 1 | Viewed by 660
Abstract
Background/Objectives: To evaluate the roles of choroidal blood flow (CBF) and choroidal thickness (CT) as predictors of macular edema recurrence in patients with treatment-naive non-ischemic branch retinal vein occlusion (BRVO) after intravitreal ranibizumab (IVR) injection. Methods: Sixteen eyes from sixteen patients with treatment-naive [...] Read more.
Background/Objectives: To evaluate the roles of choroidal blood flow (CBF) and choroidal thickness (CT) as predictors of macular edema recurrence in patients with treatment-naive non-ischemic branch retinal vein occlusion (BRVO) after intravitreal ranibizumab (IVR) injection. Methods: Sixteen eyes from sixteen patients with treatment-naive non-ischemic BRVO treated with IVR, once initially and then as needed, were included in the study. CBF and CT in the subfovea, occlusive, and non-occlusive regions were measured via laser speckle flowgraphy and enhanced depth imaging optical coherence tomography over 12 months. Results: Baseline CT was significantly greater in the occlusive region (335 ± 72.1 µm) than in the non-occlusive region (274 ± 36.7 µm, p = 0.028). CT in the occlusive region was reduced significantly after 1 week (p = 0.008), but CBF did not change significantly after IVR throughout the follow-up period (p > 0.05). The occlusive/non-occlusive region CBF ratio at baseline was significantly associated with the number of IVR injections over 12 months (mean 2.63) in patients with BRVO (p = 0.048). Conclusions: Baseline CBF imbalance in eyes with treatment-naive BRVO may indicate the recurrence of macular edema after ranibizumab therapy. Full article
(This article belongs to the Special Issue Advances in the Diagnosis of Eye Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop